EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access

CAR T‐cell therapy in large B cell lymphoma

Alexander P Boardman, Gilles Salles

Hematological Oncology · 2023-06 · 41 (S1) · 112-118

DOI: 10.1002/hon.3153 ↗

At a glance

Übersichtsarbeit in Hematological Oncology, published online on 2023-06-09. Written by Alexander P Boardman and 1 co-authors. Institution: Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, New York, USA. Major MEDLINE topics: Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms. Cited 56 times so far (Crossref); 43 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

CD19‐targeted chimeric antigen receptor (CAR) T‐cells have revolutionized the treatment of lymphoid malignancies, including large B cell lymphoma (LBCL). Following seminal early phase multicenter clinical trials published between 2017 and 2020, three CD19‐CAR T‐cell products received FDA and EMA approval designations in lymphoma in the third‐line setting, paving the way for follow‐up studies in the second‐line. Meanwhile, investigations into the applications of CAR T‐cell therapy have further broadened to treating high‐risk patients even prior to completion of first‐line conventional chemo‐immunotherapy. Furthermore, as early trials excluded patients with central nervous system involvement with lymphoma, several studies have recently shown promising efficacy of CD19‐CAR T‐cells in primary and secondary CNS lymphoma. Here we provide a detailed overview on clinical data supporting the use of CAR T‐cells in patients with LBCL.

Subjects

MeSH terms (MEDLINE)

Lymphoma, Large B-Cell, DiffuseCentral Nervous System NeoplasmsHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesAntigens, CD19Multicenter Studies as Topic

Author keywords

B-cell lymphomaCD19autologous stem cell transplantation (ASCT)chimeric antigen receptor (CAR) T celldiffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)primary CNS lymphoma (PCNSL)secondary CNS lymphoma (SCNSL)

Substances

Receptors, Antigen, T-CellAntigens, CD19

Authors and institutions

  • Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, New York, USA.

Funding

  • NCI NIH HHS

Cite

APA

Boardman, A. P., & Salles, G. (2023). CAR T‐cell therapy in large B cell lymphoma. Hematological Oncology, 41(S1), 112-118. https://doi.org/10.1002/hon.3153

Vancouver

Boardman AP, Salles G. CAR T‐cell therapy in large B cell lymphoma. Hematological Oncology. 2023;41(S1):112-118. doi:10.1002/hon.3153

BibTeX
@article{Boardman2023,
  author = {Boardman, Alexander P and Salles, Gilles},
  title = {CAR T‐cell therapy in large B cell lymphoma},
  journal = {Hematological Oncology},
  year = {2023},
  volume = {41},
  number = {S1},
  pages = {112--118},
  doi = {10.1002/hon.3153}
}
Start for free →